Close Menu

NEW YORK – California-based A2 Biotherapeutics will begin clinical development of its T-cell module platform, called Tmod, after raising $71.5 million in funding.

Existing investors, including The Column Group, Vida Ventures, Samsara BioCapita, and Nextech Invest, participated in the Series B funding round, along with new investors Casdin Capital, Euclidean Capital, UC Investments (Office of the Chief Investment Officer of the Regents), and Hartford HealthCare Endowment.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Apr
27
Sponsored by
Biognosys

This webinar, the first in our Next-Generation Proteomics for Precision Oncology series, will discuss how proteomics can help overcome the challenges of treating COVID-19 patients with oncologic comorbidities.

Jun
16
Sponsored by
Biognosys

This webinar, the second in our Next-Generation Proteomics for Precision Oncology series, will discuss how unbiased discovery proteomics can be used to identify new key mechanisms and signatures supporting clinical decision-making for melanoma patients.